Magnesium Oral Supplementation for Acute Non-specific Low Back Pain
Status:
Completed
Trial end date:
2020-03-08
Target enrollment:
Participant gender:
Summary
Acute non-specific low back pain (LBP) is one of the most common complaints at the emergency
department. It is more prevalent in countries with high-income economies, where 60-80% of the
population report back pain at some point in their life. Numerous medication options are
available for acute LBP relief such as non-steroid anti-inflammatory drugs (NSAIDs),
myorelaxant drugs, opioids, and benzodiazepines. Magnesium is a physiological
voltage-dependent blocker of N-methyl-D-aspartate NMDA)-coupled channels that can influence
inflammatory pain and neuropathic pain through several different mechanisms. In this study
the investigators aimed to investigate the effect of magnesium oral supplementation for acute
low back pain.